Seroconversion rate between March and October 2010 in 705 vaccinated participants.

NIAID Data Ecosystem2026-03-07 收录

数据链接：

https://figshare.com/articles/dataset/_Seroconversion_rate_between_March_and_October_2010_in_705_vaccinated_participants_/685752 数据链接链接失效反馈

官方服务：

资源简介：

Seroconversion rate between March and October 2010 in 705 vaccinated participants.

创建时间：

2013-04-18

Dynamic trend of neutralizing antibody GMTs (95%CI) for EV71 FCP-As.

疫苗免疫原性

中和抗体动态监测

Female BALB/c mice (4–6 weeks old) were i.p. inoculated with three EV71 FCP-As (V1, V2, and V3) containing 200 U antigen. The sera were isolated and tested at 7, 14, 21, 28, 56 and 84 d post-inoculati

NIAID Data Ecosystem100

Dataset from Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

疫苗免疫原性

疫苗安全性监测

To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy childre

NIAID Data Ecosystem10

Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a Phase 1/2 trial

COVID-19mRNA疫苗临床试验

疫苗免疫原性

Safety and immunogenicity of SW-BIC-213, a modified COVID-19 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18 years and above: a Phase 1/2 trial

NCATS Open Data2023-10-12 更新00

Cryo-EM structure of the Sars-Cov2 S trimer without RBDs

病毒蛋白结构解析

疫苗免疫原性

Cryo-EM structure of the Sars-Cov2 S trimer without RBDs Descriptor: Spike glycoprotein,Fibritin Authors: Effantin, G. Deposit date: 2023-11-28 Release date: 2024-12-11 Last modified: 2025-07-02 Metho

Protein Data Bank Japan2025-07-02 更新40

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

新冠疫苗I期临床试验

疫苗免疫原性

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

NCATS Open Data2022-11-08 更新00